Glucocorticoid-induced osteoporosis

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 5, 2001, Pages 589-595

  Kumar, Rajiv ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM ION; CYTOKINE; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SALCATONIN; TESTOSTERONE; VITAMIN D;

AGING; BONE DENSITY; CALCIUM HOMEOSTASIS; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TESTOSTERONE METABOLISM;

ANIMALS; BONE AND BONES; CALCIUM; DIPHOSPHONATES; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; VITAMIN D;

EID: 0034859602     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200109000-00007     Document Type: Review

References (69)

1. The basophil adenomas of the pituitary body and their clinical manifestations
2. Quantitative microradiographic study of bone remodeling in Cushing's syndrome
3. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: Study in eumenorrheic patients with Cushing's syndrome
4. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis
5. Steroid-induced fractures and bone loss in patients with asthma
6. Rapid loss of vertebral mineral density after renal transplantation
7. Osteoporosis after cardiac transplantation
8. Bone loss after heart transplantation: A prospective study
9. Fracture after cardiac transplantation: A prospective longitudinal study
10. Bone loss and turnover after cardiac transplantation
11. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry
12. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae
13. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells
14. Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms
15. Basal activities and hormone responsiveness of osteoclast-like and osteoblast-like bone cells are regulated by glucocorticoids
16. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone
17. Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes
18. Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats
19. The effects of hydrocortisone, parathyroid hormone and the bisphosphonate, APD, on bone resorption in neonatal mouse calvaria
20. Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro
21. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2
22. Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells
23. Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells
24. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
25. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
26. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
27. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
28. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
29. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
30. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
31. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
32. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids
33. Glucocorticoid osteoporosis
34. Glucocorticoid osteoporosis - Mechanisms and management
35. Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess
36. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man
37. Effect of cortisone treatment on the active transport of calcium by the small intestine
38. Effects of 1,25-dihydroxycholecalciferol on intestinal calcium transport in cortisone-treated rats
39. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy
40. Effects of prednisone on vitamin D metabolism in man
41. Effect of glucocorticoids on function of the parathyroid glands in man
42. Calcium and phosphorus homeostasis in man. Effect of corticosteroids
43. Osteopenia in patients with rheumatic diseases: Principles of diagnosis and therapy
44. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration
45. Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: Evidence for dissociation between calcium absorption and brush border vesicle uptake
46. 3 induced DNA dependent RNA polymerase activity in chick intestinal cells
47. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
48. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
49. Testosterone therapy in glucocorticoid-treated men
50. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin
51. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
52. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis
53. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
54. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followup
55. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial
56. Prevention of corticosteroid-induced osteoporosis by alfacalcidol
57. Effect of calcitriol on bone loss after cardiac or lung transplantation
58. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
59. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
60. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis
61. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy
62. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
63. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
64. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies
65. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study
66. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy
67. Corticosteroid-induced osteoporosis
68. Corticosteroid osteoporosis: Practical implications of recent trials
69. UK consensus group on management of glucocorticoid-induced osteoporosis: An update